I had guessed that January's drop was connected to Illumina's announcement in the same month, so was surprised that it reversed in April.
Unconfigured Ad
Collapse
X
-
My guess (and it's really just a guess) is that they are ignoring the X Ten in figuring the prices. Illumina has been raising prices on their sequencing kits every April 1st, so that little bump makes sense. However, I'm not sure that they're taking into account the release of the v4 chemistry for the HiSeq 2500. That reduced the list price for 1Gb of sequence from $43 down to $29. (For comparison, it's just $7/Gb for the HiSeq X.)Originally posted by xyzzy123 View PostI had guessed that January's drop was connected to Illumina's announcement in the same month, so was surprised that it reversed in April.
Comment
-
https://www.genome.gov/sequencingcosts/ is no longer being updated. It looks like they hit the end of the graph and don't want to extend it. In any case, since the price is now dropping much more _slowly_ than Moore's Law, in another 10 years or so at this rate Moore's Law will catch up and the graph would look kind of silly.
Comment
-
Due to all the artificial limitations on the X10, I don't consider it an accurate reflection of real sequencing costs.
Comment
-
Indeed. Those costs are misleading. There should be all sorts of asterisks detailing the assumptions. Might as well throw in the higher per-base cost of using PacBio to complete a genome.Originally posted by Brian Bushnell View PostDue to all the artificial limitations on the X10, I don't consider it an accurate reflection of real sequencing costs.
I've always hated that graph because of the misapplication of "Moore's Law". Stupid. But I have seen it in so many presentations that I just grit my teeth.
Comment
Latest Articles
Collapse
-
by SEQadmin2
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...-
Channel: Articles
Today, 11:01 AM -
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Today, 02:55 AM
|
0 responses
7 views
0 reactions
|
Last Post
by SEQadmin2
Today, 02:55 AM
|
||
|
Started by SEQadmin2, 07-24-2026, 12:17 PM
|
0 responses
12 views
0 reactions
|
Last Post
by SEQadmin2
07-24-2026, 12:17 PM
|
||
|
Started by SEQadmin2, 07-23-2026, 11:41 AM
|
0 responses
12 views
0 reactions
|
Last Post
by SEQadmin2
07-23-2026, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
24 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|
Comment